Key result
Growth hormone-releasing hormone antagonists ameliorate ocular inflammation and pterygium, while synthetic somatostatin analogs support corneal wound healing and immunology.
Key points are not available for this paper at this time.
May offer novel targets for ocular surface disease; leaves open clinical translation in humans.
Growth hormone-releasing hormone antagonists (GHRHAnt)-which induce ATF6 13ameliorate LPS-induced ocular inflammation 14 and pterygium.15 Synthetic somatostatin analogs support corneal wound healing, 16 are involved in corneal immunology, 17 and induceFinancial disclosures/conflicts of interest: None reported.
No takes yet. Share an insight, caveat, or question.
Nektarios Barabutis (2025) studied this question. Growth hormone-releasing hormone antagonists ameliorate ocular inflammation and pterygium, while synthetic somatostatin analogs support corneal wound healing and immunology.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: